OTC: HLUBF - H. Lundbeck A/S

半年間の収益性: -27.38%
配当利回り: +16.83%
セクタ: Healthcare

プロモーションスケジュール H. Lundbeck A/S

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について H. Lundbeck A/S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia.

さらに詳しく
It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 16.83
Дивиденд ао 0.7
Сайт https://www.lundbeck.com
Цена ао 4.43
1日あたりの価格変動: 0% (4.43)
週ごとの価格変動: 0% (4.43)
月ごとの料金変更: 0% (4.43)
3ヶ月間の価格変動: -15.09% (5.2175)
半年間の価格変動: -27.38% (6.1)
年間の価格変動: +3.87% (4.265)
3年間の価格推移: 0% (4.43)
5年間の価格推移: 0% (4.43)
10年間の価格推移: 0% (4.43)
年初からの価格変動: -15.62% (5.25)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 1.39 9
P/BV 0.1858 10
P/E 12.08 8
EV/EBITDA 4.3 10
合計: 9.38

効率

名前 意味 学年
ROA, % 0.9065 1
ROE, % 1.54 1
合計: 2.5

配当金

名前 意味 学年
Div yield, % 16.83 10
DSI 1 10
合計: 8.41

義務

名前 意味 学年
Debt/EBITDA 5.05 0
合計: 6

成長の衝動

名前 意味 学年
収益性 Revenue, % -83.42 0
収益性 Ebitda, % -81.03 0
収益性 EPS, % -97.51 0
合計: 1.6
さらに詳しく

機関 音量 共有, %
Vanguard International Stock Index-Total Intl Stock Indx 766645 0.38
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 448123 0.23
iShares Core MSCI EAFE ETF 373578 0.19
DFA International Small Cap Value Portfolio 233923 0.12
iShares MSCI EAFE Small Cap ETF 208316 0.1
Vanguard Intl Equity Index Fds-FTSE All World ex U.S. Index Fund 124308 0.06
Vanguard International Stock Index-Vanguard European Stock Index 124066 0.06
iShares Core MSCI Total International Stock ETF 96483 0.05
Dimensional ETF Tr-Dimensional International Small Cap Value ETF 80813 0.04
iShares MSCI Denmark ETF 77939 0.04



スーパーバイザー 役職 支払い 生年
Mr. Joerg Hornstein CFO & Executive VP of Corporate Functions 1.23M 1977 (48 年)
Mr. Lars Bang Executive Vice President of Product Development & Supply 1.14M 1962 (63 年)
Dr. Per Johan Luthman Executive Vice President of Research & Development 1.27M 1959 (66 年)
Mr. Charl van Zyl President & CEO 5.34M 1967 (58 年)
Dr. Tarek Samad Ph.D. Senior VP & Head of Research N/A
Mr. Palle Holm Olesen Chief Specialist & VP of Investor Relations N/A
Mr. Ole Chrintz Senior Vice President of International Markets N/A 1958 (67 年)
Dr. Rupert Sandbrink M.D., Ph.D. Senior VP & Head of Clinical Development N/A 1964 (61 年)
Ms. Tine Ostergaard Hansen Senior Vice President of Corporate Communications & Public Affairs N/A 1975 (50 年)
Ms. Dianne Holto Executive Vice President of People & Culture 1973 (52 年)

住所: Denmark, Valby, Ottiliavej 9 - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.lundbeck.com